Published in Antimicrob Agents Chemother on June 01, 1999
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother (2002) 2.03
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother (2010) 1.36
P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother (2009) 1.23
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother (2007) 1.09
Skin and skin structure infections: treatment with newer generation fluoroquinolones. Ther Clin Risk Manag (2007) 0.90
Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother (2001) 0.88
Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis. Antimicrob Agents Chemother (2008) 0.86
Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag (2006) 0.85
Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Antimicrob Agents Chemother (2009) 0.85
Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. Antimicrob Agents Chemother (2003) 0.83
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother (2011) 0.82
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob Agents Chemother (2005) 0.82
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection (2012) 0.79
Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae. Wien Klin Wochenschr (2007) 0.79
Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia. Clin Infect Dis (2016) 0.77
Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother (2007) 0.75
In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model. Antimicrob Agents Chemother (2007) 0.75
High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis. J Anal Methods Chem (2012) 0.75
A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother (2015) 0.75
Gender analysis of moxifloxacin clinical trials. J Womens Health (Larchmt) (2013) 0.75
Evaluation of Moxifloxacin-induced Biochemical Changes in Mice. Indian J Pharm Sci (2012) 0.75
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother (1998) 3.60
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy (1997) 2.82
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci (2000) 5.53
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology (2000) 2.67
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther (2015) 2.34
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther (1989) 2.29
Sub-ice foraging behavior of emperor penguins. J Exp Biol (2000) 2.26
Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev (2005) 2.25
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
Human B-lymphocyte antigens expressed by lymphocytic and myelocytic leukemia cells. I. Detection by rabbit antisera. J Exp Med (1976) 2.10
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother (1988) 2.09
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Lower motor neuron degeneration associated with type C RNA virus infection in mice: neuropathological features. J Neuropathol Exp Neurol (1974) 2.00
The Veterans Affairs Continuous Improvement in Cardiac Surgery Study. Ann Thorac Surg (1994) 1.96
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother (2001) 1.84
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother (1988) 1.82
Continuous assessment and improvement in quality of care. A model from the Department of Veterans Affairs Cardiac Surgery. Ann Surg (1994) 1.80
Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology (1998) 1.79
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers. J Antimicrob Chemother (1982) 1.70
Growth factors regulate the survival and fate of cells derived from human neurospheres. Nat Biotechnol (2001) 1.70
Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother (1980) 1.68
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68
N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother (1981) 1.65
Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother (1991) 1.63
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother (1992) 1.62
SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents. J Antimicrob Chemother (1981) 1.60
Borderline increases in albumin excretion rate and the relation to glycemic control in subjects with type I diabetes. Clin Chem (1991) 1.58
The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. J Antimicrob Chemother (1999) 1.58
Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother (1989) 1.57
Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology (1981) 1.55
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
Human immunodeficiency virus seroprevalence in primary care practices in the United States. West J Med (1993) 1.50
Ultrastructural studies of multiple sclerosis. Lab Invest (1969) 1.49
Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine. Free Radic Biol Med (1992) 1.49
Sch 29482--a novel penem antibiotic: an in-vitro comparison of its activity with other beta-lactams. J Antimicrob Chemother (1982) 1.49
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J Biol Chem (1994) 1.46
Pharmacokinetics and tissue penetration of azthreonam. Antimicrob Agents Chemother (1982) 1.42
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Antimicrob Agents Chemother (1983) 1.42
Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother (2002) 1.40
Salvage angioplasty: an alternative to high risk surgery for unstable angina? Cathet Cardiovasc Diagn (1992) 1.40
The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int J Antimicrob Agents (1994) 1.38
Neuronally restricted RNA splicing regulates the expression of a novel GABAA receptor subunit conferring atypical functional properties [corrected; erratum to be published]. J Neurosci (1997) 1.38
Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother (2001) 1.38
The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother (1993) 1.38
Problems with Iso-Sensitest agar. J Antimicrob Chemother (1990) 1.38
Genitalia in human figure drawings: childrearing practices and child sexual abuse. J Pediatr (1990) 1.38
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother (1998) 1.37
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother (1993) 1.37
Effects of storage time and temperature on measurement of small concentrations of albumin in urine. Clin Chem (1990) 1.35
Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother (1998) 1.33
Comparison of sensititre dried microtitration trays with a standard agar method for determination of minimum inhibitory concentrations of antimicrobial agents. Antimicrob Agents Chemother (1980) 1.30
Tear lipocalins: potential lipid scavengers for the corneal surface. Invest Ophthalmol Vis Sci (1999) 1.30
Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax (1988) 1.29
The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother (2002) 1.27
6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors. J Antimicrob Chemother (1981) 1.27
In vitro activities of two glycylcyclines. Antimicrob Agents Chemother (1994) 1.27
Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol (2001) 1.26
Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother (1995) 1.25
Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med (1993) 1.24
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother (1995) 1.22
Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J Virol (1996) 1.22
The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother (1998) 1.22
Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother (1988) 1.21
In vitro activity of CGP 31608, a new penem. Antimicrob Agents Chemother (1987) 1.21
Impact of mammary grafts on coronary bypass operative mortality and morbidity. Department of Veterans Affairs Cardiac Surgeons. Ann Thorac Surg (1994) 1.19
Control of the rhesus monkey menstrual cycle: permissive role of hypothalamic gonadotropin-releasing hormone. Science (1980) 1.19
Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother (1989) 1.19
Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA (1991) 1.19
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother (1999) 1.19
Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis (1988) 1.18
No continuous relationship between Veterans Affairs hospital coronary artery bypass grafting surgical volume and operative mortality. Ann Thorac Surg (1996) 1.18
Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax (1990) 1.18
Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax (1991) 1.18
In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother (1992) 1.17
The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone. J Antimicrob Chemother (1993) 1.17
Experimental induction of puberty in the infantile female rhesus monkey. Science (1980) 1.17
Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother (1991) 1.16